MTOR and nonpapillary renal cell carcinoma: Several drugs such as tyrosine kinase inhibitors, programmed death 1 checkpoint inhibitors, and mechanistic target of rapamycin (mTOR) inhibitors have been used for the treatment of metastatic ccRCC.2